Almac Group, the global contract pharmaceutical development and manufacturing organisation (CDMO), has announced record-breaking financial results for its fiscal year ending 30 September 2024. The company posted £1.027 billion in revenue, a 7% increase from the previous year, alongside a
“We are privately owned by a Trust, which means all our profits are reinvested in the company. This translates to steady growth – maybe slower compared to other service providers, but we’re quite proud of that steady growth,” explains Franciane
Almac Group, a global contract development and manufacturing organisation (CDMO), has confirmed an £11 million investment aimed at expanding its analytical services capabilities. This initiative will also lead to the creation of over 100 new jobs across its global operations.
Almac Contract Manufacturing & Development (CDMO) Profile The Almac Group is an established CMDO providing integrated drug development services to the Biopharma industry. Addressing the pressure to bring clinical candidates through the pipeline more efficiently and at a lower cost,
Almac Pharma Services, part of the Almac Group, has successfully supported the commercial packaging and rapid launch of BioLineRx’s APHEXDA® (motixafortide) into the US market. The treatment, approved by the FDA on 11 September 2023, is used to mobilise hematopoietic
Partnering with a Contract Development and Manufacturing Organisation (CDMO) offers several significant advantages for pharmaceutical companies. Almac’s Global Heads of Business Development, Brian Eastwood (Almac Pharma Services) and Simon Hamilton (Almac Sciences) discuss the key benefits in more detail. Why
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
